Advertisement

Annals of Hematology

, Volume 96, Issue 7, pp 1097–1104 | Cite as

A retrospective study evaluating the impact of infectious complications during azacitidine treatment

  • Anna SchuckEmail author
  • Marie-Christine Goette
  • Judith Neukirchen
  • Andrea Kuendgen
  • Norbert Gattermann
  • Thomas Schroeder
  • Guido Kobbe
  • Ulrich Germing
  • Rainer Haas
Original Article

Abstract

Azacitidine has become an available therapy for high-risk myelodysplastic syndromes. Infectious complications (IC) may impede the success of therapy. Since most patients are managed in an outpatient setting, often with low level of clinical and microbiological documentation, the impact of IC remains unclear. We retrospectively evaluated the clinical course of 77 patients with MDS treated with azacitidine between 2004 and 2015 (median age 69 years). Clinical workup included severity and type of IC, days in the hospital and with antimicrobial therapy, response to azacitidine, and overall survival (OS). In total, 614 azacitidine cycles were administered, 81 cycles with at least one IC. The median number of administered cycles was 6 (range 1–43). Median OS after the start of azacitidine was 17 months (range 1–103). Infection rates were higher in the first 3 cycles with bacterial infections leading. The better patients’ hematological response to azacitidine with less IC occurred, and fewer days with antimicrobial treatment were needed. Compared to progressive disease, stable disease made no significant improvement in occurrence of IC and days in the hospital. Older age was associated with more IC and longer time in the hospital. Comorbidities or IPSS-R had no influence on IC. The incidence of IC correlated with hematological response and age. Stable disease led to longer OS, but incidence of IC was comparable to progressive disease and survival seemed to be bought by a considerable number of IC. IC rates were highest in the first 3 cycles. We recommend response evaluation after 4–6 cycles.

Keywords

Myelodysplastic syndromes Azacitidine Infectious complications Clinical course 

Notes

Compliance with ethical standards

Conflict of interest

Anna Schuck: Financial travel support from Celgene.

Judith Neukirchen: Financial travel support and speakers honorarium from Celgene.

Andrea Kündgen: Financial travel support from Celgene.

Thomas Schroeder: Financial travel support, research funding, lecture fees from Celegene.

Guido Kobbe: Research funding, financial travel support and lecture fees from Celgene.

Ullrich Germing: Speakers honorarium from Celgene, Janssen-Cilag, Novartis, Research support Celgene, Novartis.

Human and animal rights and informed consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Kuendgen A, Strupp C, Aivado M et al (2006) Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 24:5358–5365CrossRefPubMedGoogle Scholar
  2. 2.
    Xicoy B, Jiménez M, García et al (2013) Results of treatment with azacitidine in patients aged ≥75 years included in the Spanish Registry of Myelodysplastic Syndromes. Leuk Lymphoma 55:1300–1303CrossRefPubMedGoogle Scholar
  3. 3.
    Germing U, Kobbe G, Haas R et al (2013) Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int 110:783–790PubMedPubMedCentralGoogle Scholar
  4. 4.
    Neukirchen J, Lauseker M, Blum S et al (2014) Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leuk Res 38:57–64CrossRefPubMedGoogle Scholar
  5. 5.
    Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kaminskas E, Farrell AT, Wang YC et al (2005) FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10:176–182CrossRefPubMedGoogle Scholar
  7. 7.
    Miller KB, Kim K, Morrison FS et al (1992) The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 65:162–168CrossRefPubMedGoogle Scholar
  8. 8.
    Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429–2440CrossRefPubMedGoogle Scholar
  9. 9.
    Silverman LR, Holland JF, Demakos EP et al (1994) Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol 68:A12Google Scholar
  10. 10.
    Silverman LR, Holland JF, Ellison RR (1990) Low dose continuous infusion azacytidine is an effective therapy for patients with myelodysplastic syndromes, a study of Cancer and Leukemia Group B. J Cancer Res Clin Oncol 116(suppl):816Google Scholar
  11. 11.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562–569CrossRefPubMedGoogle Scholar
  13. 13.
    Nachtkamp K, Stark R, Strupp C et al (2016) Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol 95:937–944CrossRefPubMedGoogle Scholar
  14. 14.
    Mufti GJ, International Working Group on Morphology of myelodysplastic syndrome et al (2008) Diagnosis and classification of myelodysplastic syndrome: international Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93:1712–1717CrossRefPubMedGoogle Scholar
  15. 15.
    Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the international Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425CrossRefPubMedGoogle Scholar
  16. 16.
    Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for prognosis in myelodysplastic syndromes. Blood 89:2079PubMedGoogle Scholar
  17. 17.
    De Pauw B, Walsh T, Donnely et al (2009) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821CrossRefGoogle Scholar
  18. 18.
    Della Porta MG, Malcoavti L, Strupp C et al (2011) Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 96:441–449CrossRefPubMedGoogle Scholar
  19. 19.
    Merkel D, Filanovsky K, Gafter-Gvili A et al (2013) Predicting infections in high-risk patients with myelodyslastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol 88:130–134CrossRefPubMedGoogle Scholar
  20. 20.
    Ofran Y, Filanovsky K, Gafter-Gvili A et al (2015) Higher infection rate after 7-compared with 5- day cycle of Azacitidine in patients with higher-risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk 15:e95–e99CrossRefPubMedGoogle Scholar
  21. 21.
    Pomares H, Arnan M, Sánchez-Ortega I et al (2016) Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering fungal prophylaxis? Mycoses 59:516–519CrossRefPubMedGoogle Scholar
  22. 22.
    Knipp S, Hildebrand B, Kündgen A et al (2007) Intensive chemotherapy is not recommended for patients aged > 60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 110:345–352CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Anna Schuck
    • 1
    Email author
  • Marie-Christine Goette
    • 1
  • Judith Neukirchen
    • 1
  • Andrea Kuendgen
    • 1
  • Norbert Gattermann
    • 1
  • Thomas Schroeder
    • 1
  • Guido Kobbe
    • 1
  • Ulrich Germing
    • 1
  • Rainer Haas
    • 1
  1. 1.Department of Hematology, Oncology and Clinical ImmunologyHeinrich Heine UniversityDüsseldorfGermany

Personalised recommendations